

# ASIAMEDIC LIMITED

(Incorporated in the Republic of Singapore)  
(Company Registration No. 197401556E)

## MATERIAL VARIANCES BETWEEN THE UNAUDITED FINANCIAL RESULTS ANNOUNCEMENT AND AUDITED FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025 (“FY2025”)

The Board of Directors (the “**Board**”) of AsiaMedic Limited (the “**Company**”, and together with its subsidiaries, collectively the “**Group**”) refers to its unaudited FY2025 financial results announcement dated 1 March 2026 (the “**Unaudited Results**”) and its audited financial statements in the annual report for FY2025 (the “**Audited Financial Statements**”) dated on 13 April 2026.

Pursuant to Rule 704(5) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited, the Board wishes to announce the below material variances between the Unaudited Results and the Audited Financial Statements following the finalisation of audit by the external auditors, Baker Tilly TFW LLP.

### Extract of Consolidated Statement of Comprehensive Income FY2025

	The Group				Note
	Audited Financial Statements	Unaudited Results	Variance increase / (decrease)		
	S\$	S\$	S\$	%	
<b>Group</b>					
Other income	1,698,244	818,733	879,511	107	Note A
Impairment loss on financial assets - associate	-	(1,030,873)	1,030,873	100	Note A
Gain from deconsolidation of subsidiary	-	1,682,784	(1,682,784)	(100)	Note A
Gain from disposal of subsidiary	-	227,600	(227,600)	(100)	Note A

### Extract of Statements of Financial Position as at 31 December 2025

	Audited Financial Statements	Unaudited Results	Variance increase / (decrease)		Note
	S\$	S\$	S\$	%	
	<b>Group</b>				
Other receivables and deposits	1,784,002	1,274,388	509,614	40	Note B
Other payables and accruals	3,448,112	2,938,498	509,614	17	Note B
Other reserves	137,210	(515,334)	652,544	127	Note C
Accumulated losses	(16,823,141)	(17,475,685)	(652,544)	(4)	Note C
<b>Company</b>					
Other receivables and deposits	4,665,726	3,634,852	1,030,874	28	Note D
Accumulated losses	(19,603,762)	(20,634,636)	(1,030,874)	(5)	Note D

## **Explanatory Notes:**

### **Group-level variances**

#### **A. Disposal and deconsolidation of AsiaMedic Astique The Aesthetic Company (“AATAC”)**

The variances arose from the finalisation of the accounting for the disposal and deconsolidation of AATAC. The Group completed the disposal of 60% interest in AATAC on 31 October 2025 and consequently, AATAC became a 40% associated company of the Company and was deconsolidated from the Group from that date.

In the Audited Financial Statements, the gain on deconsolidation, gain on disposal and the related impairment of receivables from AATAC have been reclassified and presented on a net basis within “Other income”, whereas these items were previously presented separately in the Unaudited Results.

#### **B. Intercompany elimination adjustments**

The variances in other receivables and other payables of \$509,614 each arose from the correction of over-elimination of intercompany balances between these line items. These adjustments are reclassification in nature and have no impact on the Group’s net assets, profit or cash flows.

#### **C. Reclassification within equity**

The variance of \$652,544 between other reserves and accumulated losses of the Group relates to the reclassification of put option reserves to accumulated losses following the exercise of put options in prior years. This represents a presentation adjustment within equity and has no impact on total equity.

### **Company-level variances**

#### **D. Reversal of impairment**

The variances at the Company level were attributable to the reversal of impairment loss on amounts owing by an associate following the finalisation of audit.

This resulted in:

- (a) an increase in other receivables of approximately \$1.03 million; and
- (b) a corresponding reduction in accumulated losses,

leading to an increase in the Company’s profit for FY2025.

Shareholders are advised to read the Audited Financial Statements set out in the FY2025 Annual Report for further details.

Shareholders and investors are advised to exercise caution when dealing in the Company's shares. When in doubt, shareholders and potential investors are advised to seek independent advice from their professional advisers before trading or making any investment decision on the Company's securities.

### **By Order of the Board**

Foo Soon Soo (Ms)  
Company Secretary

13 April 2026

---

*This announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954.*